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Abstract A chimera of an N-terminally modi¢ed insulin
growth factor (IGF)-II, NQPQMVHTY-hIGF-II(9^67) (BO-
MIGF), fused to interleukin-3 (IL-3) signi¢cantly improved
the migration of CD34+ human hematopoietic cells with respect
to the e¡ects observed during co-stimulation with BOMIGF and
IL-3. A phosphatidylinositol-3 (PI-3) kinase inhibitor speci¢-
cally inhibited migration in the presence of the chimera, while
no signi¢cant di¡erence in the inhibition of migration was ob-
served in the presence of a Rho kinase inhibitor. These results
suggest a key role of the PI-3 kinase pathway in the potentia-
tion of migration caused by the linkage of BOMIGF and IL-
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1. Introduction
Our laboratory has been studying the synergistic hemato-
poietic e¡ects associated with the delivery of factors as fusion
proteins of insulin growth factors (IGFs) and cytokines. We
are able to produce, using the baculovirus expression system,
a biologically active and secreted form of a slightly modi¢ed
IGF-II, NQPQMVHTY-hIGF-II(9^67) (BOMIGF), which
contains the leader sequence and the ¢rst nine amino acids
of bombyxin (an insect insulin like peptide) [1]. By joining the
cDNA of a cytokine of choice to the sequence of BOMIGF
within a baculovirus expression vector, we were able to gen-
erate high yields of chimeric proteins [2]. We have produced,
by this system, a fusion protein of BOMIGF and interleukin-3
(IL-3) (BOMIGF^IL-3), which potentiated hematopoietic cell
proliferation [3] and cell survival (DiFalco, Ali and Congote,
submitted) as compared with the e¡ects observed when the
single components of the chimera were added simultaneously.
Treatment with BOMIGF^IL-3 increases the number of hem-
atopoietic precursor cells found in bone marrow and spleen
tissues of myelosuppressed C57BL/6 mice [4]. In normal mice,
the increase of hematopoietic stem cell precursors caused by
BOMIGF^IL-3 was observed especially in the spleen [3]. This
result may be attributed to a preferential ability by the chi-
mera to mobilize stem cells from bone marrow and lead to
increased accumulation of stem cells in the spleen. These ob-
servations prompted us to analyze the e¡ect of the chimera on
migration of the CD34þ hematopoietic cell line TF-1 in vitro.
CD34þ stem cells are present in small amounts in circula-
tion during steady-state hematopoiesis as part of a normally
occurring tra⁄cking of hematopoietic stem cells between the
bone marrow and other hematopoietic organs such as the
spleen and liver. This process is particularly crucial in facili-
tating bone marrow recovery following hematopoietic stress
such as cytotoxic chemotherapy. Although the mechanism for
the mobilization of stem cells into peripheral blood is still
poorly understood, it is thought to require increased prolifer-
ation of early progenitor cells followed by their migration and
egress from the bone marrow cavities. Several hematopoietic
growth factors, and in particular IL-3, as well as complex
adhesive interactions between stem cell surface binding mole-
cules and their ligands found in the extracellular matrix and/
or on bone marrow stromal accessory cells play a key role in
the mobilization process [5^7]. Although the role of IGFs on
hematopoietic cell mobility has not been well characterized,
there are many reports on the action of IGFs on migration of
a variety of cells such as trophoblasts [8], smooth muscle cells
[9,10] and heart ¢broblasts [11]. In the case of IGFs, the
chemotactic activities seem to be mediated by di¡erent signal
transduction pathways, including phosphatidylinositol-3 (PI-
3) kinase [12], protein kinase C (PKC) [13], Rho kinase [14]
and phosphorylation of the mitogen-activated protein kinase
(MAPK) [8,11]. MAPK activation seems to be dependent on
upstream increased tyrosine phosphorylation of focal adhe-
sion kinase (FAK) mediated by the IGF-I receptor. The re-
quirement of FAK phosphorylation is still unsettled, probably
due to variations in responses observed within the same cells
having a di¡erent cytoskeletal architecture [15^17]. The same
signal transduction pathways are involved in the mechanism
of action of IL-3, albeit in studies based mainly on the e¡ects
of the cytokine on proliferation and survival [18^23].
The e¡ects of IGFs and IL-3 on migration are the result of
a complex cross-talk between the growth factors and integrins.
K4L1 integrin is important for the action of IL-3 in CD34þ
progenitor cells [5], whereas K5L1, KVL5, K2L1 and KVL3 are
involved in the action of IGFs, depending on the interacting
component of the extracellular matrix, such as ¢bronectin,
vitronectin or collagen [24^26]. The action of IGFs on migra-
tion is also a¡ected by IGF binding proteins [24]. In this
communication we show how the linkage of BOMIGF with
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IL-3 results in an improved chemotactic activity for hemato-
poietic cells.
2. Materials and methods
2.1. Materials
Recombinant BOMIGF and the recombinant chimera of BOMIGF
with human IL-3 were produced as previously described [3]. Human
IL-3 was from RpD Systems. Fibronectin was from BD Biosciences.
All kinase inhibitors were from Calbiochem, with the exception of Y-
27632, obtained from Tocris. Exoenzyme C3 was from Upstate Bio-
technology. The peptides RGDS and RGES were from Peninsula
Laboratories. Anti-L1 integrin antibody (anti-CD29) was from Beck-
man^Coulter.
2.2. Cell cultures
The factor-dependent human hematopoietic cell line TF-1 (Ameri-
can Tissue Type Culture Collection) was maintained in culture as
previously described [3]. Recently, we have replaced GM-CSF with
0.5 nmol/ml BOMIGF^IL-3 as a cytokine growth supplement. The
serum-free medium used for migration experiments was RPMI 1640
supplemented with 300 Wg/ml fatty acid-free, tissue culture-tested bo-
vine serum albumin (BSA; Sigma) and 30 Wg/ml bovine transferrin
(ICN).
2.3. Cell migration assay
Migration experiments were performed using Transwell (Costar)
chambers equipped with ¢lter membranes with pore sizes of 5 or 8 Wm
in diameter [27], as indicated in the individual experiments. TF-1
cells were incubated in starvation medium (RPMI 1640 medium with
0.5% fetal calf serum and 300 Wg/ml BSA) for 18 h. Subsequently, cells
were washed, resuspended in the serum-free medium indicated above
and 1.5U105 cells were dispensed into the upper chamber of Costar
Transwells. Growth factors were added to the lower chamber at a
¢nal concentration of 0.1^25 mM. After a 16 h incubation at 37‡C,
cells in the bottom chamber were collected, mixed with trypan blue
(vital stain) and counted with a hemocytometer under a light micro-
scope. In experiments where the e¡ects of ¢bronectin were studied, the
Transwells were preincubated with 10 Wg/ml ¢bronectin in RPMI 1640
medium alone for 3 h at 37‡C prior to addition of cells. In experiments
in the presence of inhibitors, the cells were incubated ¢rst for 20 min
with the inhibitors. The cytokines were added subsequently and the
incubation continued for 18 h. RGDS and RGES were added together
with the cytokines. For the experiments with exoenzyme C3, the cells
were electropermeabilized with the exoenzyme as described by Laudan-
na et al. [28], but without addition of NAD.
3. Results and discussion
Fig. 1A shows the importance of ¢bronectin for the migra-
tion of TF-1 cells in Costar Transwells, where the addition of
this matrix protein considerably increases the number of cells
going through to the lower cell chamber. Cell migration was
measured by adding 25 nM BOMIGF, IL-3, the chimera and
the corresponding equimolar mixture of BOMIGF and IL-3
to the lower chamber of the Transwells. When the results
obtained after incubation of the cells with the cytokines are
expressed as percent stimulation over control cell cultures, it
was evident that the cytokines stimulated migration even in
the absence of ¢bronectin (Fig. 1B). In fact, the number of
cells migrating in the presence of the chimera was signi¢cantly
higher than that observed with the co-addition of BOMIGF
and IL-3. This is better appreciated in the dose^response
curve shown in Fig. 2A. There was a signi¢cantly higher stim-
ulation of cell migration in the presence of the chimera at
concentrations of 10 and 25 nM as compared with BOMIGF
and IL-3 added simultaneously (P6 0.05 and 0.04, respec-
tively, paired t-test). This di¡erence was not signi¢cant in
the presence of ¢bronectin (Fig. 2B). In fact, the stimulation
of migration caused by the cytokines was lower than that
observed in the absence of the cell matrix protein. These re-
sults indicate that, in the absence of ¢bronectin, the linkage of
IGF with IL-3 improves the chemotactic activity of both com-
pounds for TF-1 cells. This potentiation has also been ob-
served for the stimulation of cell proliferation [3] and cell
survival (DiFalco, Ali and Congote, submitted). Preliminary
experiments using a murine hematopoietic cell line (32DI,
grown in the presence of IGF-I and IL-3) con¢rmed the spe-
ci¢c stimulation of the chimera on cell migration. However, in
32DI cells the chimera was more active than the equimolar
mixture of BOMIGF and murine IL-3 both in the presence or
absence of ¢bronectin (DiFalco and Congote, unpublished
results).
Di¡erent signal pathways are known to be involved in the
mechanism of action of IGFs and IL-3. In order to have a
better idea of the relative importance of some of these path-
ways on the action of the chimera on migration, we ¢rst
Fig. 1. Role of ¢bronectin and cytokines on TF-1 cell migration. A: E¡ect of ¢bronectin on migration. MeanQS.E.M. n=10 and 11 for migra-
tion in control wells and wells previously coated with ¢bronectin, respectively. The di¡erence between both groups was signi¢cant (P6 0.02,
Welch’s test). B: E¡ect on migration of 25 nM BOMIGF, IL-3, BOMIGF^IL-3 (chimera) and an equimolar mixture of 25 nM each of BO-
MIGF and IL-3. The results have been expressed as percent stimulation over the number of cells migrating in the presence (+) or absence
(BSA in the medium) of ¢bronectin without cytokines (control = 100). The chimera signi¢cantly stimulated migration in the absence of ¢bronec-
tin as compared with the equimolar mixture using the paired, non-parametric Wilcoxon test (P6 0.04, n=8). These experiments were done
with Transwells of 5 Wm diameter.
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analyzed the e¡ects of di¡erent inhibitors, including those
targeting integrin interactions, on the mobility of TF-1 cells
through ¢bronectin-coated wells. In these initial experiments
we used inhibitor concentrations known to be e¡ective in
other hematopoietic cells. The PI-3 kinase inhibitor LY-
294002 decreased migration by about 45% (Fig. 3A(I)).
Although this kinase plays an important role in the actions
of both IGFs and IL-3, it seems that it is not the unique
mediator of cell migration. The PKC inhibitor stauroporine
almost completely eliminates cell migration, suggesting a crit-
ical role of the enzyme on TF-1 migration. The MAPK kinase
inhibitor PD98059, on the contrary, did not inhibit migration
at concentrations known to be e¡ective in other cell lines. As
indicated in Section 1, FAK phosphorylation is important for
MAPK activation. Although the chimera is capable of stim-
ulating FAK phosphorylation, after extensive studies under a
variety of conditions, we could not ¢nd a tangible signi¢cant
di¡erence on FAK phosphorylation displayed by the action of
the chimera or that of the mixture of individual factors (Di-
Falco and Congote, unpublished results). Fig. 3A(II) shows
Fig. 2. Dose^response curves for cell migration. Cell migration was
measured as indicated in Section 2 with increasing concentrations of
the chimera (squares) or the equivalent equimolar mixture of BO-
MIGF and IL-3 (open circles) in the absence (A) or presence (B) of
¢bronectin. Cells migrating through 8 Wm Transwells were counted
and the results are expressed as percent increase over control cell
culturesQ S.E.M. Although there was a wide variation of migration
from one experiment to the other, the paired t-test indicated that
the stimulation of cell migration at the concentrations of 10 and 25
nM in the absence of ¢bronectin was signi¢cantly higher than that
observed in the presence of BOMIGF and IL-3 added simultaneous-
ly (P6 0.05 (n=8) and P6 0.04 (n=9), respectively). No signi¢cant
di¡erences were observed in the presence of ¢bronectin.
C
Fig. 3. E¡ects of inhibitors of di¡erent signal transduction pathways
on TF-1 cell migration. A: TF-1 migration assays were performed
with Transwells (5 Wm) preincubated with ¢bronectin in the presence
of BOMIGF^IL-3. The results are expressed as percent of the val-
ues obtained with the chimera without inhibitors and the P values
were calculated by analysis of variance and Student^Keuls multiple
comparisons test. A comparison of the e¡ects obtained with 20 WM
LY-294002 (PI-3 kinase inhibitor, P6 0.01), 0.5 WM stauroporine
(PKC inhibitor, P6 0.01) and 20 WM PD-98059 (MAPK kinase in-
hibitor, non-signi¢cant). (II) E¡ects of inhibitors of the Rho path-
way. C3, e¡ect of electropermeabilized exoenzyme C3 (ADP-ribosy-
lation of Rho, P6 0.01); Rho kinase, cells incubated with 10 WM
Y-27632 (P6 0.001). (III) Inhibitors related to integrin function. L1-
integr., cells incubated with 50 Wg/ml anti-CD29, an integrin L1 sub-
unit inhibitory antibody (P6 0.001). RGDS, cells incubated with
100 WM ¢bronectin competitor peptide RGDS (P6 0.01). RGES,
cells incubated with 100 WM of the control peptide RGES (non-sig-
ni¢cant). B: E¡ect of increasing concentrations of Y-27632 on TF-1
cell migration in the presence of 10 mM chimera (squares) or 10
mM each of BOMIGF and IL-3 (open circles). The results are ex-
pressed as percent of the cell migration as compared with the migra-
tion obtained with 10 nM concentrations without inhibitor (100%).
MeanQS.E.M. (n=4). C: E¡ect of increasing concentrations of
LY-294002 on TF-1 cell migration in the presence of 10 mM chi-
mera (squares) or 10 mM each of BOMIGF and IL-3 (open circles).
The results are expressed as percent of cell migration as compared
with the migration obtained with 10 nM concentrations without in-
hibitor (100%). MeanQS.E.M. (n=4). The higher sensitivity of TF-
1 cells towards the PI-3 kinase inhibitor in the presence of the chi-
mera was signi¢cant at the concentrations of 2 and 20 WM
(P6 0.05 and P6 0.01, respectively, Student^Newman^Keuls multi-
ple comparisons test). Subs., coating substrate. Experiments B and
C were done with 8 Wm Transwells in the absence of ¢bronectin but
coated with the albumin (BSA) of the incubation medium.
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the possible involvement of the Rho kinase pathway on the
migration of TF-1 cells in the presence of the chimera. The
exoenzyme C3, originally puri¢ed from Clostridium botulinum,
is known to inactivate Rho through ADP-ribosylation [28].
C3, introduced into TF-1 cells by electroporation, was able
to considerably reduce migration. The involvement of Rho
was further con¢rmed by the inhibition of migration in the
presence of Y-27632, an inhibitor of the Rho-associated pro-
tein kinase p160ROCK [29,30]. Fig. 3A(III) shows the possi-
ble involvement of integrins containing the L1 chain on mi-
gration. The antibody against this chain eliminated migration
and the peptide RGDS, containing the integrin binding tri-
peptide RGD, substantially reduced migration. This inhibi-
tion was speci¢c for the RGD sequence, because the control
peptide RGES was unable to eliminate the chemotactic activ-
ity of the chimera.
Since the e¡ects of the chimera are far more evident in the
absence of ¢bronectin in TF-1 cells, we did not study any
further the integrin-related inhibitors indicated in Fig.
3A(III). Instead, we decided to analyze in more detail the
e¡ect of two of the four inhibitors of intracellular signal trans-
duction pathways of Fig. 3A(I,II), this time in the absence of
¢bronectin (Fig. 3B,C): Y-27632, because the Rho-associated
protein kinase is known to play a key role in migration, and
LY-294002, the inhibitor of PI-3 kinase. Although the e¡ect
of 20 WM LY-294002 was not particularly striking (Fig.
3A(I)), we have found that PI-3 kinase activity is increased
in the presence of the chimera (DiFalco, Ali and Congote,
submitted). Therefore, this enzyme is an attractive candidate
as a mediator of the preferential action of the chimera in TF-1
cells. Cells were incubated in the presence of increasing con-
centrations of Y-27632 and after 20 min solutions of 10 nM
chimera or the equivalent mixture of 10 nM BOMIGF and 10
nM IL-3 was added to the lower Transwell chamber and in-
cubated for 18 h. The migrating cells were collected and
counted. Fig. 3B shows the decrease of cell numbers with
increasing concentrations of the inhibitor. This decrease was
practically identical in the presence of the chimera or the
equimolar mixture of BOMIGF and IL-3. Therefore,
although the Rho kinase plays an important role in TF-1
cell migration, it is unlikely that the observed preferential
increase of migration in the presence of the chimera could
be attributed to a speci¢c stimulation of the Rho kinase path-
way. The same experiment was carried out using the PI-3
kinase inhibitor LY-294002 (Fig. 3C). Since the inhibition of
migration with the inhibitor was not complete at a concen-
tration of 20 WM (Fig. 3A), we extended the range of concen-
trations up to 200 WM. Fig. 3C shows that the PI-3 kinase
inhibitor preferentially inhibits the chimera-mediated migra-
tion of TF-1 cells. This increased sensitivity towards LY-
294002 was signi¢cant at concentrations of 2 and 20 WM
(P6 0.05 and P6 0.01, respectively).
It can be concluded from these experiments that the linkage
of IGF-II with IL-3 results in a synergistic e¡ect on cell mi-
gration in TF-1 cells. Although the mechanisms involved in
this preferential increase remain to be elucidated, it is clear
that the PI-3 kinase is a key player in the action of the chi-
mera. This can be deduced from the signi¢cant and speci¢c
elimination of cell migration in the presence of a PI-3 kinase
inhibitor. These results are supported by our observation that
the chimera increases the PI-3 kinase activity of TF-1 cells
(DiFalco, Ali and Congote, submitted). They provide a likely
explanation for the increased number of spleen colonies ob-
served after injection of the chimera into mice [3] and suggest
a possible use for IGF^IL-3 chimeras as a mobilizing agent in
transplantation of bone marrow hematopoietic cells. An addi-
tional advantage associated with the administration of IGF^
cytokine chimeras in vivo may be related with the presence in
serum of numerous IGF binding proteins. The latter could
potentially increase the half life of the IGF-linked cytokines
by extending the protective e¡ects they normally have for
circulating IGFs. This possibility remains to be explored.
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